Breaking News, Collaborations & Alliances

Clovis Oncology and Evergreen Theragnostics Form Partnership

Initiate development and manufacturing services agreement for Actinium-225-Labeled FAP-2286.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Clovis Oncology has entered a development, manufacturing and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286). The companies intend to develop radiolabeling chemistry and analytical methods for use in potential future pre-clinical and clinical studies. “This agreement with Evergreen Theragnostics represents an important step forward for Clovis in our efforts to optimize our clinical development program for FAP-2286,” said Patrick J. Mah...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters